The role of toll-like receptors in colorectal cancer progression: Evidence for epithelial to leucocytic transition (ELT)

Frontiers in Immunology

Volumn 5, Issue AUG, 2014, Pages

  Luddy, Kimberly A ^a   Robertson Tessi, Mark ^a   Tafreshi, Narges ^a   Soliman, Hatem ^a   Morse, David L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAS ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; L SELECTIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MYELOID DIFFERENTIATION FACTOR 88; PADGEM PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; CYTOKINE;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL TRANSFORMATION; COLORECTAL CANCER; EPITHELIAL LEUKOCYTE TRANSITION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; IMMUNE DYSREGULATION; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOSTIMULATION; PATTERN RECOGNITION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; CANCER CONTROL; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIAL TO LEUCOCYTIC TRANSITION; EPITHELIUM CELL; IMMUNOCOMPETENT CELL; INFLAMMATION; INTRACELLULAR SIGNALING; LEUKOCYTE; METASTASIS; TUMOR CELL; TUMOR INVASION;

EID: 84914178762     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00429     Document Type: Article

References (95)

1. Rahman AH, Taylor DK, Turka LA. The contribution of direct TLR signaling to T cell responses. Immunol Res. 2009;45(1):25-36. Epub 2009/07/15.
2. Lu Q, Ding H, Li W. Role of Toll-like receptors in microbiota-associated gastrointestinal cancer metastasis. J Cancer Res Ther. 2013;9 Suppl:S142-9. Epub 2014/02/12.
3. Du T, Zhou ZG, You S, Huang G, Lin J, Yang L, et al. Modulation of monocyte hyperresponsiveness to TLR ligands by 1,25-dihydroxy-vitamin D3 from LADA and T2DM. Diabetes Res Clin Pract. 2009;83(2):208-14. Epub 2008/11/18.
4. Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol. 2013;10(2):103-6. Epub 2012/12/18.
5. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499-511. Epub 2004/07/02.
6. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010;10(2):131. Epub 2010/01/26.
7. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 2002;168(2):554-61. Epub 2002/01/05.
8. Applequist SE, Wallin RP, Ljunggren HG. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol. 2002;14(9):1065-74. Epub 2002/08/31.
9. Takenaka S, McCormick S, Safroneeva E, Xing Z, Gauldie J. Influence of the tissue microenvironment on Toll-like receptor expression by CD11c+ antigenpresenting cells isolated from mucosal tissues. Clin Vaccine Immunol. 2009;16(11):1615-23. Epub 2009/09/25.
10. de Kivit S, Tobin MC, Forsyth CB, Keshavarzian A, Landay AL. Regulation of Intestinal Immune Responses through TLR Activation: Implications for Pro- and Prebiotics. Front Immunol. 2014;5:60. Epub 2014/03/07.
11. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis. 2010;16(9):1583-97. Epub 2010/08/31.
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. Epub 2011/03/08.
13. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7. Epub 2002/12/20.
14. Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, et al. Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity. Clin Cancer Res. 2013;19(6):1340-6. Epub 2012/12/29.
15. Sato Y, Goto Y, Narita N, Hoon DS. Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron. 2009;2 Suppl 1:205-14. Epub 2009/08/18.
16. Eiro N, Gonzalez L, Gonzalez LO, Fernandez-Garcia B, Andicoechea A, Barbon E, et al. Toll-like receptor-4 expression by stromal fibroblasts is associated with poor prognosis in colorectal cancer. J Immunother. 2013;36(6):342-9. Epub 2013/06/27.
17. Pradere JP, Dapito DH, Schwabe RF. The Yin and Yang of Toll-like receptors in cancer. Oncogene. 2013. Epub 2013/08/13.
18. Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai RM, et al. MyD88- mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med. 2010;207(8):1625-36. Epub 2010/07/14.
19. Yu L, Wang L, Chen S. Dual character of Toll-like receptor signaling: protumorigenic effects and anti-tumor functions. Biochim Biophys Acta. 2013;1835(2):144-54. Epub 2012/12/13.
20. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008;27(2):218-24. Epub 2008/01/08.
21. O'Leary DP, Bhatt L, Woolley JF, Gough DR, Wang JH, Cotter TG, et al. TLR-4 signalling accelerates colon cancer cell adhesion via NF-kappaB mediated transcriptional up-regulation of Nox-1. PLoS One. 2012;7(10):e44176. Epub 2012/10/17.
22. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-44. Epub 2008/07/25.
23. Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, et al. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene. 2014. Epub 2014/02/18.
24. Kwon OJ, Zhang L, Ittmann MM, Xin L. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A. 2014;111(5):E592-600. Epub 2013/12/25.
25. Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res. 2010;29:92. Epub 2010/07/14.
26. Montero Vega MT, de Andres Martin A. The significance of toll-like receptors in human diseases. Allergol Immunopath. 2009;37(5):252-63. Epub 2009/10/27.
27. Lu H. TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects. Front Immunol. 2014;5:83. Epub 2014/03/14.
28. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005;65(12):5009-14. Epub 2005/06/17.
29. Killeen SD, Wang JH, Andrews EJ, Redmond HP. Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaBdependent activation of the urokinase plasminogen activator system. Br J Cancer. 2009;100(10):1589-602. Epub 2009/05/14.
30. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591-602. Epub 2005/08/02.
31. Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, del Casar JM, Lamelas ML, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10:665. Epub 2010/12/07.
32. Wang JH, Manning BJ, Wu QD, Blankson S, Bouchier-Hayes D, Redmond HP. Endotoxin/lipopolysaccharide activates NF-kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol. 2003;170(2):795-804. Epub 2003/01/09.
33. Jing YY, Han ZP, Sun K, Zhang SS, Hou J, Liu Y, et al. Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide. Bmc Med. 2012;10.
34. Alitalo K. The lymphatic vasculature in disease. Nat Med. 2011;17(11):1371. Epub 2011/11/09.
35. Das S, Sarrou E, Podgrabinska S, Cassella M, Mungamuri SK, Feirt N, et al. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J Exp Med. 2013;210(8):1509-28. Epub 2013/07/24.
36. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis. 2008;25(4):345-56. Epub 2007/09/25.
37. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010;17(3):206-25. Epub 2010/04/09.
38. Ji RC. Lymph node lymphangiogenesis: a new concept for modulating tumor metastasis and inflammatory process. Histol Histopathol. 2009;24(3):377-84. Epub 2009/01/09.
39. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann N Y Acad Sci. 2008;1131:225-34. Epub 2008/06/04.
40. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst. 2002;94(11):819-25. Epub 2002/06/06.
41. Monteleone I, Platt AM, Jaensson E, Agace WW, Mowat AM. IL-10-dependent partial refractoriness to Toll-like receptor stimulation modulates gut mucosal dendritic cell function. Eur J Immunol. 2008;38(6):1533-47. Epub 2008/05/08.
42. Fusi A, Liu Z, Kummerlen V, Nonnemacher A, Jeske J, Keilholz U. Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Transl Med. 2012;10:52. Epub 2012/03/22.
43. Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Padgaonkar VA, Guo RF, et al. Role of C5a in multiorgan failure during sepsis. J Immunol. 2001;166(2):1193-9. Epub 2001/01/06.
44. Paschos KA, Canovas D, Bird NC. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal. 2009;21(5):665-74. Epub 2009/01/27.
45. Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol. 2010;20(3):169-77. Epub 2010/05/11.
46. Alberda WJ, Dassen HP, Dwarkasing RS, Willemssen FE, van der Pool AE, de Wilt JH, et al. Prediction of tumor stage and lymph node involvement with dynamic contrast-enhanced MRI after chemoradiotherapy for locally advanced rectal cancer. Int J Colorectal Dis. 2013;28(4):573-80. Epub 2012/09/25.
47. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62(6):1832-7. Epub 2002/03/26.
48. Jain S, Sharma P, Mukherjee A, Bal C, Kumar R. "Witch's Milk" and 99mTc- Pertechnetate Uptake in Neonatal Breast Tissue: An Uncommon but not Unexpected Finding. Clin Nucl Med. 2013;38(7):586-7. Epub 2013/05/04.
49. Murakami T, Kawada K, Iwamoto M, Akagami M, Hida K, Nakanishi Y, et al. The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer. 2013;132(2):276-87. Epub 2012/06/13.
50. Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene. 2007;26(32):4679-88. Epub 2007/02/14.
51. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005;23(12):2744-53. Epub 2005/04/20.
52. Ghadjar P, Coupland SE, Na IK, Noutsias M, Letsch A, Stroux A, et al. Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol. 2006;24(12):1910-6. Epub 2006/04/20.
53. Rubie C, Oliveira V, Kempf K, Wagner M, Tilton B, Rau B, et al. Involvement of chemokine receptor CCR6 in colorectal cancer metastasis. Tumour Biol. 2006;27(3):166-74. Epub 2006/04/28.
54. Rubie C, Oliveira-Frick V, Rau B, Schilling M, Wagner M. Chemokine receptor CCR6 expression in colorectal liver metastasis. J Clin Oncol. 2006;24(32):5173-4; author reply 4. Epub 2006/11/10.
55. Rubie C, Kollmar O, Frick VO, Wagner M, Brittner B, Graber S, et al. Differential CXC receptor expression in colorectal carcinomas. Scand J Immunol. 2008;68(6):635-44. Epub 2008/10/31.
56. Iwasa S, Yanagawa T, Fan J, Katoh R. Expression of CXCR4 and its ligand SDF- 1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis. Anticancer Res. 2009;29(11):4751-8. Epub 2009/12/25.
57. Matsusue R, Kubo H, Hisamori S, Okoshi K, Takagi H, Hida K, et al. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF- 1/CXCR4 axis. Ann Surg Oncol. 2009;16(9):2645-53. Epub 2009/07/10.
58. Ghadjar P, Rubie C, Aebersold DM, Keilholz U. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer. 2009;125(4):741-5. Epub 2009/05/30.
59. Cambien B, Karimdjee BF, Richard-Fiardo P, Bziouech H, Barthel R, Millet MA, et al. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer. 2009;100(11):1755-64. Epub 2009/05/14.
60. Guillemot E, Karimdjee-Soilihi B, Pradelli E, Benchetrit M, Goguet-Surmenian E, Millet MA, et al. CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver. Br J Cancer. 2012;107(12):1944-9. Epub 2012/11/22.
61. Strell C, Entschladen F. Extravasation of leukocytes in comparison to tumor cells. Cell Commun Signal. 2008;6:10. Epub 2008/12/06.
62. Vega MTM, Martin AD. The significance of toll-like receptors in human diseases. Allergol Immunopath. 2009;37(5):252-63.
63. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer. 2002;101(5):415-22. Epub 2002/09/07.
64. Koretz K, Schlag P, Boumsell L, Moller P. Expression of VLA-alpha 2, VLAalpha 6, and VLA-beta 1 chains in normal mucosa and adenomas of the colon, and in colon carcinomas and their liver metastases. Am J Pathol. 1991;138(3):741-50. Epub 1991/03/01.
65. Liapis H, Flath A, Kitazawa S. Integrin alpha V beta 3 expression by boneresiding breast cancer metastases. Diagn Mol Pathol. 1996;5(2):127-35. Epub 1996/06/01.
66. Seftor RE, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E, et al. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci U S A. 1992;89(5):1557-61. Epub 1992/03/01.
67. Man YG, Stojadinovic A, Mason J, Avital I, Bilchik A, Bruecher B, et al. Tumorinfiltrating immune cells promoting tumor invasion and metastasis: existing theories. J Cancer. 2013;4(1):84-95. Epub 2013/02/07.
68. Holzel M, Bovier A, Tuting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer. 2013;13(5):365-76. Epub 2013/03/29.
69. Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1-2):43-73. Epub 2012/12/15.
70. Tarin D. Inappropriate gene expression in human cancer and its far-reaching biological and clinical significance. Cancer Metastasis Rev. 2012;31(1-2):21-39. Epub 2011/12/06.
71. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV, et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol. 2012;181(4):1115-25. Epub 2012/09/05.
72. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 2005;65(14):5996-6000; discussion -1. Epub 2005/07/19.
73. Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer. 2011;11(7):512-22. Epub 2011/06/28.
74. Schramm HM. Should EMT of Cancer Cells Be Understood as Epithelial- Myeloid Transition? J Cancer. 2014;5(2):125-32. Epub 2014/02/05.
75. Pawelek JM. Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol. 2005;6(12):988-93. Epub 2005/12/03.
76. Pawelek JM, Chakraborty AK. The cancer cell--leukocyte fusion theory of metastasis. Adv Cancer Res. 2008;101:397-444. Epub 2008/12/06.
77. Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nat Rev Immunol. 2013;13(5):309-20. Epub 2013/04/20.
78. Brinkman CC, Peske JD, Engelhard VH. Peripheral tissue homing receptor control of naive, effector, and memory CD8 T cell localization in lymphoid and nonlymphoid tissues. Front Immunol. 2013;4:241. Epub 2013/08/24.
79. Tufail S, Badrealam KF, Sherwani A, Gupta UD, Owais M. Tissue specific heterogeneity in effector immune cell response. Front Immunol. 2013;4:254. Epub 2013/08/30.
80. Erreni M, Bianchi P, Laghi L, Mirolo M, Fabbri M, Locati M, et al. Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol. 2009;460:105-21. Epub 2009/05/19.
81. Hwang TL, Lee LY, Wang CC, Liang Y, Huang SF, Wu CM. CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis. World J Gastroenterol. 2012;18(11):1249-56. Epub 2012/04/03.
82. Kitayama J, Nagawa H, Tsuno N, Osada T, Hatano K, Sunami E, et al. Laminin mediates tethering and spreading of colon cancer cells in physiological shear flow. Br J Cancer. 1999;80(12):1927-34. Epub 1999/09/02.
83. Roy J, Audette M, Tremblay MJ. Intercellular adhesion molecule-1 (ICAM-1) gene expression in human T cells is regulated by phosphotyrosyl phosphatase activity. Involvement of NF-kappaB, Ets, and palindromic interferon-gammaresponsive element-binding sites. J Biol Chem. 2001;276(18):14553-61. Epub 2001/03/30.
84. Ding YB, Chen GY, Xia JG, Zang XW, Yang HY, Yang L. Association of VCAM-1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World J Gastroenterol. 2003;9(7):1409-14. Epub 2003/07/11.
85. Burdick MM, Chu JT, Godar S, Sackstein R. HCELL is the major E- and Lselectin ligand expressed on LS174T colon carcinoma cells. J Biol Chem. 2006;281(20):13899-905. Epub 2006/03/28.
86. Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol. 1993;4(4):219-29. Epub 1993/08/01.
87. Caruso RA, Fedele F, Finocchiaro G, Arena G, Venuti A. Neutrophil-tumor cell phagocytosis (cannibalism) in human tumors: an update and literature review. Exp Oncol. 2012;34(3):306-11. Epub 2012/10/17.
88. Song J, Sapi E, Brown W, Nilsen J, Tartaro K, Kacinski BM, et al. Roles of Fas and Fas ligand during mammary gland remodeling. J Clin Invest. 2000;106(10):1209-20. Epub 2000/11/22.
89. Mullauer L, Mosberger I, Grusch M, Rudas M, Chott A. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol. 2000;190(1):20-30. Epub 2000/01/21.
90. Spriggs DR, Imamura K, Rodriguez C, Sariban E, Kufe DW. Tumor necrosis factor expression in human epithelial tumor cell lines. J Clin Invest. 1988;81(2):455 Epub 1988/02/01.
91. Humbert L, Lebrun JJ. TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system. Cell Signal. 2013;25(2):490-500. Epub 2012/10/23.
92. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011;128(4):887-96. Epub 2010/05/18.
93. Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One. 2013;8(10):e76012. Epub 2013/10/15.
94. Koscielny S, Le MG, Tubiana M. The natural history of human breast cancer. The relationship between involvement of axillary lymph nodes and the initiation of distant metastases. Br J Cancer. 1989;59(5):775-82. Epub 1989/05/01.
95. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999;17(8):2334-40. Epub 1999/11/24.